Cart
sales@molnova.com
TMBIM6 antagonist-1
CAS No. 123134-61-2
TMBIM6 antagonist-1( BIA )
Catalog No. M22371 CAS No. 123134-61-2
TMBIM6 antagonist-1 is an antagonist of TMBIM6.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 111 | In Stock |
|
| 5MG | 177 | In Stock |
|
| 10MG | 299 | In Stock |
|
| 25MG | 537 | In Stock |
|
| 50MG | 767 | In Stock |
|
| 100MG | 1053 | In Stock |
|
| 500MG | 2115 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTMBIM6 antagonist-1
-
NoteResearch use only, not for human use.
-
Brief DescriptionTMBIM6 antagonist-1 is an antagonist of TMBIM6.
-
DescriptionTMBIM6 antagonist-1 is an antagonist of TMBIM6.
-
In VitroCell Viability Assay Cell Line:HT1080, MCF7, MDA-MB-2341 and SKBR3 cells.Concentration:0.5-10 μM.Incubation Time:3 days.Result:Inhibited cell viability.Western Blot Analysis Cell Line:WT and TMBIM6 KO HT1080 cells.Concentration:0, 2, 5 μM.Incubation Time:Result:Downregulated the protein levels of AKT-pS473.
-
In VivoAnimal Model:Six- to eight-week BklNbt:BALB/c/nu/nu old mice (HT1080 and MDA-MB-231 cells).Dosage:1?mg/kg.Administration:IP 5 days per week during 25 days.Result:Impaired cell-driven tumor growth.
-
SynonymsBIA
-
PathwayPI3K/Akt/mTOR signaling
-
TargetmTOR
-
RecptorTMBIM6
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number123134-61-2
-
Formula Weight268.27
-
Molecular FormulaC15H12N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (186.38 mM)
-
SMILESNc1ccccc1C(=O)\C=C\c1cccc(c1)[N+]([O-])=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kim H K , Bhattarai K R , Junjappa R P , et al. TMBIM6/BI-1 contributes to cancer progression through assembly with mTORC2 and AKT activation[J]. Nature Communications, 2020, 11(1).
molnova catalog
related products
-
CID3528206
CID3528206 is a potent, small molecule yeast TORC1 inhibitor that inhibits TORC1 activity both in vitro and in vivo with IC50 of 150 nM and 3.9 uM, respectively.
-
XL413 hydrochloride
XL-413 is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity.
-
Seco Rapamycin sodiu...
Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR.
